Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amplia Therapeutics ( (AU:ATX) ) has provided an update.
Amplia Therapeutics has received Australian ethics clearance to initiate a Phase 2 clinical trial of its FAK inhibitor, narmafotinib, in combination with FOLFIRINOX chemotherapy for advanced pancreatic cancer patients. This trial, which follows US ethics approval, aims to identify the optimal dose of narmafotinib and will be conducted at sites in Australia and the USA. The trial’s outcome could enhance Amplia’s position in the oncology sector by potentially offering a more effective treatment option for pancreatic cancer, thereby impacting stakeholders positively.
More about Amplia Therapeutics
Amplia Therapeutics Limited is an Australian pharmaceutical company focused on developing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company has a particular emphasis on fibrotic cancers such as pancreatic and ovarian cancer, and FAK is also relevant in chronic diseases like idiopathic pulmonary fibrosis (IPF).
Average Trading Volume: 6,967,119
Technical Sentiment Signal: Buy
Current Market Cap: A$93.52M
For detailed information about ATX stock, go to TipRanks’ Stock Analysis page.